潤達醫療(603108.SH)實控人朱文怡質押的669.6萬股展期
格隆匯8月19日丨潤達醫療(603108.SH)公佈,公司於2019年8月19日收到公司控股股東、實際控制人朱文怡的通知。
2019年8月16日,朱文怡將其持有的公司669.6萬股無限售流通股質押給國金證券,期限至2020年2月15日。該等股份是朱文怡於2016年8月19日質押給國金證券,此次質押是對上述質押融資的續貸,不涉及新的融資安排。
朱文怡及其一致行動人劉輝合計持有公司股份約1.5945億股,佔公司股份總數的27.51%,累計合計質押股份數量約1.3199億股,佔公司股份總數的22.78%,佔兩人合計持有公司股份總數的82.78%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.